Free Trial

Coherus Oncology (CHRS) Short Interest Ratio & Short Volume

Coherus Oncology logo
$0.92 +0.04 (+4.04%)
Closing price 04:00 PM Eastern
Extended Trading
$0.91 -0.01 (-0.64%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Coherus Oncology Short Interest Data

Coherus Oncology (CHRS) has a short interest of 31.23 million shares. This marks a -2.22% decrease in short interest from the previous month. The short interest ratio (days to cover) is 22.5, indicating that it would take 22.5 days of the average trading volume of 1.69 million shares to cover all short positions.

Current Short Interest
31,230,000 shares
Previous Short Interest
31,940,000 shares
Change Vs. Previous Month
-2.22%
Dollar Volume Sold Short
$26.53 million
Short Interest Ratio
22.5 Days to Cover
Last Record Date
July 15, 2025
Outstanding Shares
115,930,000 shares
Percentage of Shares Shorted
26.94%
Today's Trading Volume
970,662 shares
Average Trading Volume
1,693,101 shares
Today's Volume Vs. Average
57%
Short Selling Coherus Oncology?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Coherus Oncology and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CHRS Short Interest Over Time

CHRS Days to Cover Over Time

CHRS Percentage of Float Shorted Over Time

Coherus Oncology Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
7/15/202531,230,000 shares $26.53 million -2.2%N/A22.5 $0.85
6/30/202531,940,000 shares $23.36 million No Change30.0%21.2 $0.73
6/15/202531,940,000 shares $24.33 million -1.8%30.0%20.1 $0.76
5/31/202532,530,000 shares $25.24 million -1.8%30.4%18 $0.78
5/15/202533,120,000 shares $25.44 million +1.7%30.9%18.1 $0.77
4/30/202532,570,000 shares $33.55 million -1.4%N/A18.8 $1.03
4/15/202533,030,000 shares $35.01 million +1.7%30.9%16.6 $1.06
3/31/202532,490,000 shares $26.22 million -0.2%30.4%16.7 $0.81
3/15/202532,550,000 shares $29.95 million +5.8%30.4%15.7 $0.92
2/28/202530,770,000 shares $34.15 million -3.3%28.7%12.4 $1.11
2/15/202531,810,000 shares $37.54 million +2.9%29.7%6.9 $1.18
1/31/202530,900,000 shares $36.46 million +3.7%N/A6.2 $1.18
1/15/202529,790,000 shares $43.49 million -3.0%N/A6 $1.46
12/31/202430,720,000 shares $42.39 million -1.1%N/A6.2 $1.38
12/15/202431,070,000 shares $50.02 million +1.1%N/A6.1 $1.61
11/30/202430,720,000 shares $37.48 million -7.0%N/A6 $1.22
11/15/202433,040,000 shares $24.58 million +4.9%N/A11.7 $0.74
10/31/202431,510,000 shares $23.47 million +5.6%N/A12.6 $0.75
10/15/202429,850,000 shares $27.17 million +6.8%N/A13.4 $0.91
9/30/202427,960,000 shares $29.08 million +11.4%N/A13 $1.04
9/15/202425,090,000 shares $32.62 million -0.2%N/A12.6 $1.30
8/31/202425,150,000 shares $34.96 million +4.8%N/A14.7 $1.39
8/15/202424,010,000 shares $37.22 million +6.0%N/A13.6 $1.55
7/31/202422,660,000 shares $34.90 million -1.6%N/A13.1 $1.54
7/15/202423,020,000 shares $37.98 million -0.1%N/A14 $1.65
6/30/202423,040,000 shares $39.86 million +3.8%N/A13.8 $1.73
6/15/202422,200,000 shares $37.52 million +0.6%N/A13.2 $1.69
5/31/202422,060,000 shares $40.15 million +1.3%N/A11.4 $1.82
5/15/202421,780,000 shares $47.48 million +0.4%N/A9.9 $2.18
4/30/202421,690,000 shares $42.51 million +0.7%N/A9.4 $1.96
4/15/202421,530,000 shares $47.37 million -8.2%N/A7.6 $2.20
3/31/202423,450,000 shares $56.05 million -9.5%N/A6.2 $2.39
3/15/202425,910,000 shares $57.52 million +7.1%N/A4.5 $2.22
2/29/202424,200,000 shares $55.18 million -4.4%N/A4.1 $2.28
2/15/202425,320,000 shares $72.16 million -10.0%N/A4.3 $2.85
1/31/202428,130,000 shares $60.48 million +2.6%N/A4.1 $2.15
1/15/202427,430,000 shares $70.50 million +13.2%N/A3.8 $2.57
12/31/202324,230,000 shares $80.69 million +1.9%N/A3.9 $3.33
12/15/202323,770,000 shares $51.58 million +10.8%N/A4.5 $2.17
11/30/202321,460,000 shares $45.71 million -1.1%N/A4.9 $2.13
Capital Gains Tax Strategies for Seniors (Ad)

Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.

Click here to see the three strategies and get matched with a financial advisor today.
11/15/202321,690,000 shares $39.04 million +9.3%N/A5.1 $1.80
10/31/202319,840,000 shares $66.46 million +6.0%N/A5.3 $3.35
10/15/202318,720,000 shares $71.32 million +6.4%N/A7 $3.81
9/30/202317,600,000 shares $65.82 million +21.1%N/A6.1 $3.74
9/15/202314,530,000 shares $71.49 million -7.2%N/A4.9 $4.92
8/31/202315,650,000 shares $83.41 million -0.3%N/A4.8 $5.33
8/15/202315,700,000 shares $70.18 million +16.7%N/A4.6 $4.47
7/31/202313,450,000 shares $64.83 million +6.9%N/A3.5 $4.82
7/15/202312,580,000 shares $51.07 million -16.4%N/A3.7 $4.06
6/30/202315,040,000 shares $64.22 million +15.4%N/A4.8 $4.27
6/15/202313,030,000 shares $70.23 million +0.2%N/A4.7 $5.39
5/31/202313,010,000 shares $53.21 million +9.3%N/A6.5 $4.09
5/15/202311,900,000 shares $58.19 million +12.9%N/A7.7 $4.89
4/30/202310,540,000 shares $76.20 million -4.1%N/A9.9 $7.23
4/15/202310,990,000 shares $86.60 million -7.3%N/A11.1 $7.88
3/31/202311,850,000 shares $81.05 million -1.7%N/A11.2 $6.84
3/15/202312,050,000 shares $77.00 million +22.5%N/A9.6 $6.39
2/28/20239,840,000 shares $66.62 million +0.8%N/A8 $6.77
2/15/20239,760,000 shares $77.01 million +2.3%13.4%8.5 $7.89
1/31/20239,540,000 shares $80.90 million -6.2%13.1%7.7 $8.48
1/15/202310,170,000 shares $106.28 million +2.1%14.0%8.1 $10.45
12/30/20229,960,000 shares $78.88 million +2.9%13.7%8 $7.92
12/15/20229,680,000 shares $71.15 million -4.4%13.3%9.2 $7.35
11/30/202210,130,000 shares $69.49 million +1.5%13.9%10 $6.86
11/15/20229,980,000 shares $79.44 million +7.1%13.7%9.2 $7.96
10/31/20229,320,000 shares $81.08 million +0.3%12.8%9 $8.70
10/15/20229,290,000 shares $76.92 million -3.4%12.8%8.6 $8.28
9/30/20229,620,000 shares $92.45 million +2.3%13.2%8.9 $9.61
9/15/20229,400,000 shares $98.98 million -1.2%12.9%8.5 $10.53
8/31/20229,510,000 shares $106.32 million -8.6%13.1%8.6 $11.18
8/15/202210,400,000 shares $144.25 million -1.8%14.3%9.8 $13.87
7/31/202210,590,000 shares $89.70 million +7.5%14.6%9.5 $8.47
7/15/20229,850,000 shares $78.50 million -10.4%13.6%9.2 $7.97
6/30/202210,990,000 shares $79.57 million +13.1%15.2%10.4 $7.24
6/15/20229,720,000 shares $58.22 million -4.6%13.4%9.4 $5.99
5/31/202210,190,000 shares $74.79 million +0.8%14.1%10.8 $7.34
5/15/202210,110,000 shares $80.37 million +16.2%14.0%11.1 $7.95
4/30/20228,700,000 shares $78.65 million +13.7%12.0%9.8 $9.04
4/15/20227,650,000 shares $85.99 million +0.1%10.6%8.7 $11.24
3/31/20227,640,000 shares $98.63 million +9.0%10.6%8.6 $12.91
3/15/20227,010,000 shares $87.91 million -1.3%9.7%8.1 $12.54
2/28/20227,100,000 shares $83.71 million -5.2%9.9%8.2 $11.79
2/15/20227,490,000 shares $98.87 million +13.8%10.4%8.6 $13.20
1/31/20226,580,000 shares $81.33 million -4.1%9.2%8.3 $12.36
1/15/20226,860,000 shares $95.35 million -3.7%9.6%9.7 $13.90
12/31/20217,120,000 shares $113.64 million +4.4%9.9%11.4 $15.96
12/15/20216,820,000 shares $117.24 million -4.5%9.5%10.6 $17.19
11/30/20217,140,000 shares $132.59 million +1.4%9.9%11.2 $18.57
11/15/20217,040,000 shares $133.20 million -6.3%9.8%10.9 $18.92
10/29/20217,510,000 shares $125.64 million -0.1%10.5%10.9 $16.73
Elon’s BIGGEST warning yet? (Ad)

Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.

Click here to see why Tesla's about to prove everyone wrong... again.
10/15/20217,520,000 shares $127.84 million +1.5%10.5%11.5 $17.00
9/30/20217,410,000 shares $119.08 million -13.4%10.4%10.7 $16.07
9/15/20218,560,000 shares $135.16 million -11.9%12.0%12.9 $15.79
8/31/20219,720,000 shares $155.33 million +5.4%13.7%15.1 $15.98
8/13/20219,220,000 shares $128.43 million -1.3%13.0%13.5 $13.93
7/30/20219,340,000 shares $121.89 million +0.2%13.3%13.3 $13.05
7/15/20219,320,000 shares $122.37 million -2.0%13.2%12.4 $13.13
6/30/20219,510,000 shares $131.52 million -1.9%13.5%12.1 $13.83
6/15/20219,690,000 shares $136.73 million -3.2%13.8%11.1 $14.11
5/28/202110,010,000 shares $131.73 million -5.3%14.1%11.1 $13.16
5/14/202110,570,000 shares $146.82 million -5.4%N/A10 $13.89
4/30/202111,170,000 shares $164.20 million -16.8%16.4%10.3 $14.70
4/15/202113,420,000 shares $186.00 million -3.0%19.7%10.2 $13.86
3/31/202113,840,000 shares $199.99 million +1.9%20.3%10.2 $14.45
3/15/202113,580,000 shares $220.68 million +1.2%19.9%10 $16.25
2/26/202113,420,000 shares $204.66 million +2.6%19.7%10.2 $15.25
2/12/202113,080,000 shares $246.17 million -2.3%19.4%11.5 $18.82
1/29/202113,390,000 shares $259.77 million -11.3%19.8%12.2 $19.40
1/15/202115,100,000 shares $271.65 million -2.5%22.4%15.2 $17.99
12/31/202015,490,000 shares $272.16 million +6.1%22.9%17.6 $17.57
12/15/202014,600,000 shares $265.28 million -3.9%21.6%17.2 $18.17
11/30/202015,190,000 shares $282.84 million -3.6%22.5%17.2 $18.62
11/15/202015,760,000 shares $281.16 million -3.1%23.3%17.8 $17.84
10/30/202016,260,000 shares $278.86 million -3.0%24.1%17.9 $17.15
10/15/202016,770,000 shares $306.56 million -5.6%25.1%17.4 $18.28
9/30/202017,760,000 shares $325.72 million -5.9%26.5%18.4 $18.34
9/15/202018,870,000 shares $353.06 million +1.6%28.5%18.7 $18.71
8/31/202018,580,000 shares $352.46 million +3.2%28.1%17.4 $18.97
8/14/202018,010,000 shares $343.45 million -3.3%27.5%12.4 $19.07

CHRS Short Interest - Frequently Asked Questions

What is Coherus Oncology's current short interest?

Short interest is the volume of Coherus Oncology shares that have been sold short but have not yet been closed out or covered. As of July 15th, traders have sold 31,230,000 shares of CHRS short. Learn More on Coherus Oncology's current short interest.

What is a good short interest ratio for Coherus Oncology?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CHRS shares currently have a short interest ratio of 22.0. Learn More on Coherus Oncology's short interest ratio.

Which institutional investors are shorting Coherus Oncology?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Coherus Oncology: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Coherus Oncology's short interest increasing or decreasing?

Coherus Oncology saw a decline in short interest in July. As of July 15th, there was short interest totaling 31,230,000 shares, a decline of 2.2% from the previous total of 31,940,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Coherus Oncology's short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Coherus Oncology: Erasca, Inc. (12.31%), Tectonic Therapeutic, Inc. (18.11%), iTeos Therapeutics, Inc. (6.94%), Vigil Neuroscience, Inc. (1.40%), Aquestive Therapeutics, Inc. (10.08%), Eton Pharmaceuticals, Inc. (13.30%), Astria Therapeutics, Inc. (6.78%), Fulcrum Therapeutics, Inc. (9.10%), Prothena Corporation plc (11.25%), Olema Pharmaceuticals, Inc. (11.17%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks.

What does it mean to sell short Coherus Oncology stock?

Short selling CHRS is an investing strategy that aims to generate trading profit from Coherus Oncology as its price is falling. CHRS shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Coherus Oncology?

A short squeeze for Coherus Oncology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CHRS, which in turn drives the price of the stock up even further.

How often is Coherus Oncology's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CHRS, twice per month. The most recent reporting period available is July, 15 2025.




This page (NASDAQ:CHRS) was last updated on 8/12/2025 by MarketBeat.com Staff
From Our Partners